<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26716830</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>06</Month>
        <Day>27</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>12</Issue>
            <PubDate>
              <Year>2015</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparison of the Novel Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in the Initial and Long-Term Treatment and Prevention of Venous Thromboembolism: Systematic Review and Network Meta-Analysis.</ArticleTitle>
        <Pagination>
          <StartPage>e0144856</StartPage>
          <MedlinePgn>e0144856</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0144856</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0144856</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Anticoagulation with low molecular weight heparin and vitamin K antagonists is the current standard of care (SOC) for venous thromboembolism (VTE) treatment and prevention. Although novel oral anti-coagulants (NOACs) have been compared with SOC in this indication, no head-to-head randomised controlled trials (RCTs) have directly compared NOACs. A systematic review and network meta-analysis (NMA) were conducted to compare the efficacy and safety of NOACs for the initial and long-term treatment of VTE.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Electronic databases (accessed July 2014) were systematically searched to identify RCTs evaluating apixaban, dabigatran, edoxaban, and rivaroxaban versus SOC. Eligible patients included adults with an objectively confirmed deep vein thrombosis (DVT), pulmonary embolism (PE) or both. A fixed-effect Bayesian NMA was conducted for outcomes of interest, and results were presented as relative risks (RR) and 95% credible intervals (Crl).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Six Phase III RCTs met criteria for inclusion: apixaban (one RCT; n = 5,395); rivaroxaban (two RCTs; n = 3,423/4,832); dabigatran (two RCTs; n = 2,539/2,568); edoxaban (one RCT; n = 8,240). There were no statistically significant differences between the NOACs with regard to the risk of 'VTE and VTE-related death. Apixaban treatment was associated with the most favourable safety profile of the NOACs, showing a statistically significantly reduced risk of 'major or clinically relevant non-major (CRNM) bleed' compared with rivaroxaban (0.47 [0.36, 0.61]), dabigatran (0.69 [0.51, 0.94]), and edoxaban (0.54 [0.41, 0.69]). Dabigatran was also associated with a significantly lower risk of 'major or CRNM bleed' compared with rivaroxaban (0.68 [0.53, 0.87]) and edoxaban (0.77 [0.60, 0.99]).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Indirect comparisons showed statistically similar reductions in the risk of 'VTE or VTE-related death for all NOACs. In contrast, reductions in 'major or CRNM bleed' for initial/long-term treatment were significantly better with apixaban compared with all other NOACs, and with dabigatran compared with rivaroxaban and edoxaban. Results from the current analysis indicate that the NOACs offer clinical benefit over conventional therapy while highlighting relative differences in their bleeding profile.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Cohen</LastName>
            <ForeName>A T</ForeName>
            <Initials>AT</Initials>
            <AffiliationInfo>
              <Affiliation>Guy's and St Thomas' Hospitals, King's College, London, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamilton</LastName>
            <ForeName>M</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>BMS, Princeton, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mitchell</LastName>
            <ForeName>S A</ForeName>
            <Initials>SA</Initials>
            <AffiliationInfo>
              <Affiliation>Abacus International, Bicester, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Phatak</LastName>
            <ForeName>H</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>BMS, Princeton, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>X</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, New York, United States of America.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bird</LastName>
            <ForeName>A</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer, Walton Oaks, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tushabe</LastName>
            <ForeName>D</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>TUSH-D UK LTD, Birmingham, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Batson</LastName>
            <ForeName>S</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Abacus International, Bicester, United Kingdom.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
          <PublicationType UI="D000078182">Systematic Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>30</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011728">Pyridones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>3Z9Y7UWC1J</RegistryNumber>
          <NameOfSubstance UI="C522181">apixaban</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NDF7JZ4M3</RegistryNumber>
          <NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I0VM4M70GC</RegistryNumber>
          <NameOfSubstance UI="D000069604">Dabigatran</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>NDU3J18APO</RegistryNumber>
          <NameOfSubstance UI="C552171">edoxaban</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069604" MajorTopicYN="N">Dabigatran</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011728" MajorTopicYN="N">Pyridones</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054556" MajorTopicYN="N">Venous Thromboembolism</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Competing Interests: </b>The authors have the following interests. This study was funded by Bristol Myers Squibb and Pfizer. Hamilton M. and Phatak H. are employed by Bristol Myers Squibb., Liu X. and Bird A. by Pfizer Ltd, Batson S. by Abacus International and Tushabe D. by TUSH-D UK LTD. At the time of this study, Claflin A. was a paid contractor of Pfizer Ltd. Cohen A. is a paid clinical consultant to Bristol Myers Squibb and Pfizer. Fowler H., Mitchell S.A., and Batson S. are paid consultants to Bristol Myers Squibb and Pfizer Ltd. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2015</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2015</Year>
          <Month>11</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2015</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>6</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26716830</ArticleId>
        <ArticleId IdType="pmc">PMC4696796</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0144856</ArticleId>
        <ArticleId IdType="pii">PONE-D-15-27664</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Archives of Internal Medicine. 2000;160(6):761–8. Epub 2000/03/29. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10737275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prandoni P, Noventa F, Ghirarduzzi A, Pengo V, Bernardi E, Pesavento R, et al.
The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica. 2007;92(2):199–205. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17296569</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630–6. 10.1161/CIRCULATIONAHA.109.925214
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.109.925214</ArticleId>
            <ArticleId IdType="pubmed">20351233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29(3):298–310. 10.1161/ATVBAHA.108.182428
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/ATVBAHA.108.182428</ArticleId>
            <ArticleId IdType="pubmed">19228602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. Journal of Medical Economics. 2011;14(1):65–74. Epub 2011/01/13. 10.3111/13696998.2010.546465
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3111/13696998.2010.546465</ArticleId>
            <ArticleId IdType="pubmed">21222564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Dobesh PP. Economic burden of venous thromboembolism in hospitalized patients. Pharmacotherapy:The Journal of Human Pharmacology &amp; Drug Therapy. 2009;29(8):943–53. Epub 2009/07/30. 10.1592/phco.29.8.943 [pii]. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1592/phco.29.8.943</ArticleId>
            <ArticleId IdType="pubmed">19637948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prandoni P, Kahn SR. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol. 2009;145(3):286–95. Epub 2009/02/19. 10.1111/j.1365-2141.2009.07601.x
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2141.2009.07601.x</ArticleId>
            <ArticleId IdType="pubmed">19222476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lang IM. Chronic thromboembolic pulmonary hypertension—not so rare after all. New England Journal of Medicine. 2004;350(22):2236–8. Epub 2004/05/28. 10.1056/NEJMp048088
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp048088</ArticleId>
            <ArticleId IdType="pubmed">15163772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. The American Journal of Medicine. 2013;126(9):832 e13-21. 10.1016/j.amjmed.2013.02.024
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.amjmed.2013.02.024</ArticleId>
            <ArticleId IdType="pubmed">23830539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, et al.
Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thrombosis and Haemostasis. 2007;98(4):756–64. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17938798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Venous thromboembolism in adult hospitalizations—United States, 2007–2009. MMWR Morb Mortal Wkly Rep. 2012;61(22):401–4. Epub 2012/06/08. doi: mm6122a1 [pii]. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22672974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hass B, Pooley J, Harrington AE, Clemens A, Feuring M. Treatment of venous thromboembolism—effects of different therapeutic strategies on bleeding and recurrence rates and considerations for future anticoagulant management. Thrombosis Journal. 2012;10(1):24 Epub 2013/01/02. 10.1186/1477-9560-10-24
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1477-9560-10-24</ArticleId>
            <ArticleId IdType="pmc">PMC3554503</ArticleId>
            <ArticleId IdType="pubmed">23276253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute for Health and Care Excellence. CG92: Venous thromboembolism—reducing the risk. 2010. Available: http://guidance.nice.org.uk/CG92 Accessed May 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>
Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic T, et al.
Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S–47S. 10.1378/chest.1412S3
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.1412S3</ArticleId>
            <ArticleId IdType="pmc">PMC3278060</ArticleId>
            <ArticleId IdType="pubmed">22315257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al.
Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2013;31(17):2189–204. 10.1200/JCO.2013.49.1118
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2013.49.1118</ArticleId>
            <ArticleId IdType="pubmed">23669224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, et al.
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S–88S. 10.1378/chest.11-2292
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2292</ArticleId>
            <ArticleId IdType="pmc">PMC3278051</ArticleId>
            <ArticleId IdType="pubmed">22315269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nicolaides A, Fareed J, Kakkar A, Breddin H, Goldhaber S, Hull R, et al.
Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). International Angiology. 2006;25(2):101–61. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16763532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Weitz JI. New oral anticoagulants: a view from the laboratory. American Journal of Hematology. 2012;87
Suppl 1:S133–6. 10.1002/ajh.23139
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.23139</ArticleId>
            <ArticleId IdType="pubmed">22407747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Einstein Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, et al.
Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine. 2010;363(26):2499–510. 10.1056/NEJMoa1007903
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1007903</ArticleId>
            <ArticleId IdType="pubmed">21128814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Einstein-PE Investigators, Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, et al.
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England Journal of Medicine. 2012;366(14):1287–97. 10.1056/NEJMoa1113572
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1113572</ArticleId>
            <ArticleId IdType="pubmed">22449293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al.
Oral apixaban for the treatment of acute venous thromboembolism. The New England Journal of Medicine. 2013;369(9):799–808. 10.1056/NEJMoa1302507
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1302507</ArticleId>
            <ArticleId IdType="pubmed">23808982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al.
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–72. 10.1161/CIRCULATIONAHA.113.004450
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.113.004450</ArticleId>
            <ArticleId IdType="pubmed">24344086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hokusai VTE Investigators, Buller HR, Decousus H, Grosso MA, Mercuri M, Middeldorp S, et al.
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. The New England Journal of Medicine. 2013;369(15):1406–15. 10.1056/NEJMoa1306638
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1306638</ArticleId>
            <ArticleId IdType="pubmed">23991658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al.
Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The New England Journal of Medicine. 2009;361(24):2342–52. 10.1056/NEJMoa0906598
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa0906598</ArticleId>
            <ArticleId IdType="pubmed">19966341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al.
Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S–94S. 10.1378/chest.11-2301
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.11-2301</ArticleId>
            <ArticleId IdType="pmc">PMC3278049</ArticleId>
            <ArticleId IdType="pubmed">22315268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Institute for Health and Care Excellence. The guidelines manual. London: National Institute for Health and Care Excellence; 2009. Available: http://www.nice.org.uk/guidelinesmanual Accessed May 2014.</Citation>
        </Reference>
        <Reference>
          <Citation>Dias S, Welton, N.J., Sutton, A.J. &amp; Ades, A.E. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. www.nicedsuorg.uk. 2011.</Citation>
        </Reference>
        <Reference>
          <Citation>
Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, et al.
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal. 2013;11(1):21
10.1186/1477-9560-11-21
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1477-9560-11-21</ArticleId>
            <ArticleId IdType="pmc">PMC3850944</ArticleId>
            <ArticleId IdType="pubmed">24053656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Palareti G. Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It. Scientifica. 2012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3820456</ArticleId>
            <ArticleId IdType="pubmed">24278687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis. 2005;3(4):692–4. 10.1111/j.1538-7836.2005.01204.x
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2005.01204.x</ArticleId>
            <ArticleId IdType="pubmed">15842354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 
2011.</Citation>
        </Reference>
        <Reference>
          <Citation>
Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM, et al.
The epidemiology of venous thromboembolism in the community. Thrombosis and Haemostasis. 2001;86(1):452–63. Epub 2001/08/07. doi: 01070452 [pii]. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11487036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. Journal of Thrombosis and Haemostasis: JTH. 2005;3(8):1611–7. 10.1111/j.1538-7836.2005.01415.x
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2005.01415.x</ArticleId>
            <ArticleId IdType="pubmed">16102026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Galie N, et al.
2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2014;35(43):3033–69, 69a-69k. 10.1093/eurheartj/ehu283
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehu283</ArticleId>
            <ArticleId IdType="pubmed">25173341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Beyer-Westendorf J, Buller H. External and internal validity of open label or double-blind trials in oral anticoagulation: better, worse or just different?
Journal of Thrombosis and Haemostasis. 2011;9(11):2153–8. 10.1111/j.1538-7836.2011.04507.x
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2011.04507.x</ArticleId>
            <ArticleId IdType="pubmed">21920015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ. 2012;345:e7498
10.1136/bmj.e7498
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.e7498</ArticleId>
            <ArticleId IdType="pmc">PMC3496553</ArticleId>
            <ArticleId IdType="pubmed">23150473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Kang N, Sobieraj DM. Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism. Thrombosis Research. 2014;133(6):1145–51. 10.1016/j.thromres.2014.03.035
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.thromres.2014.03.035</ArticleId>
            <ArticleId IdType="pubmed">24713109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
van der Hulle T, Kooiman J, den Exter PL, Dekkers OM, Klok FA, Huisman MV. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis: JTH. 2014;12(3):320–8. 10.1111/jth.12485
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jth.12485</ArticleId>
            <ArticleId IdType="pubmed">24330006</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. Journal of Thrombosis and Haemostasis. 2008;6(8):1313–8. Epub 2008/06/11. 10.1111/j.1538-7836.2008.03054.x
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2008.03054.x</ArticleId>
            <ArticleId IdType="pubmed">18541000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Castellucci LA, Cameron C, Le Gal G, Rodger MA, Coyle D, Wells PS, et al.
Clinical and safety outcomes associated with treatment of acute venous thromboembolism: a systematic review and meta-analysis. JAMA. 2014;312(11):1122–35. 10.1001/jama.2014.10538
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2014.10538</ArticleId>
            <ArticleId IdType="pubmed">25226478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2015;39(2):155–65. 10.1007/s11239-014-1102-5
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11239-014-1102-5</ArticleId>
            <ArticleId IdType="pubmed">24989022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Spencer FA, Gore JM, Reed G, Lessard D, Pacifico L, Emery C, et al.
Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thrombosis and Haemostasis. 2009;101(5):878–85. Epub 2009/05/01. doi: 09050878 [pii]. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2827872</ArticleId>
            <ArticleId IdType="pubmed">19404541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Nieto JA, Camara T, Gonzalez-Higueras E, Ruiz-Gimenez N, Guijarro R, Marchena PJ, et al.
Clinical outcome of patients with major bleeding after venous thromboembolism. Findings from the RIETE Registry. Thrombosis and Haemostasis. 2008;100(5):789–96. Epub 2008/11/08. doi: 08110789 [pii]. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18989522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Prandoni P, Trujillo-Santos J, Sanchez-Cantalejo E, Dalla Valle F, Piovella C, Pesavento R, et al.
Major bleeding as a predictor of mortality in patients with venous thromboembolism: findings from the RIETE Registry. Journal of thrombosis and haemostasis. 2010;8(11):2575–7. Epub 2010/08/26. 10.1111/j.1538-7836.2010.04039.x
.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1538-7836.2010.04039.x</ArticleId>
            <ArticleId IdType="pubmed">20735724</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
